Glenamrk Pharmaceutical Company on Saturday said it has launched Anti-viral Drug Favipiravir/FabiFlu for the treatment of patients with mild or moderate infected with Coronavirus.
The drug firm on Friday got approval for manufacturing and marketing from the Drugs Controller General of India.
FabiFlu is the first oral Favipiravir approved medication for the treatment of Coronavrius, the company stated.
Glenn Saldanha, Glenmark pharmaceutical chairman and director said, This aproval comes at a time when cases in India are increasing like never before, putting a huge pressure on the healthcare system.
The Pharmaceutical company hopes that the availability of an effective teatment such as FabiFlu will considerably help assuage the pressure, and offer patients in India a much needed and timely therapy option, he added.